$GEHC · GE HealthCare Technologies Inc.
GE HealthCare filed an 8-K reporting Q3 FY2026 results and a leadership change. Revenue hit $5.513B (+7.2% YoY), diluted EPS reached $1.36 vs $0.98, and Adjusted EBIT margin expanded to 16.6%. The company raised full-year 2026 guidance across revenue, EPS, and free cash flow. Separately, Patient Care Solutions President & CEO Jeannette Bankes resigned to take a CEO role elsewhere; Neal Sandy will succeed her on November 16, 2026.
- Revenue of $5.513B, up 7.2% YoY with organic growth of 6.2% across all three segments.
- Diluted EPS of $1.36 vs $0.98 prior year; Adjusted EPS of $1.34 vs $1.07, up 25.1%.
- Adjusted EBIT margin expanded 180 bps to 16.6%, driven by volume, price, cost productivity, and favorable net tariff impact.
- FY2026 guidance raised: Adjusted EPS to $4.95-$5.05 (from $4.80-$5.00), organic revenue growth to ~4.0%.
- Jeannette Bankes, President & CEO of Patient Care Solutions, resigns effective November 15, 2026; Neal Sandy named successor.
Extended-hours trading shows shares up 5.46% to $74.99 vs the $71.11 regular close, reflecting a strong positive reaction to the beat-and-raise quarter. The $32.12B market-cap company delivered results ahead of its own expectations across all segments.
Beat-and-raise quarter with 180 bps margin expansion and a raised FY2026 outlook signals accelerating operational momentum across all three business segments.
GE HealthCare's 6.2% organic revenue growth and margin expansion outpaces typical med-tech peers, with Pharmaceutical Diagnostics leading at 13.8% organic growth. The SOFIE acquisition signals consolidation in the high-growth radiopharmaceuticals/therapeutics supply chain.
PCS segment president departure creates near-term leadership transition risk, though an internal successor with 30+ years of experience has been named. The $945M SOFIE Biosciences acquisition adds integration and regulatory-closing risk into H1 2027.